Leidos was founded in 1969 and is headquartered in Reston, US

Chairman & Chief Executive Officer

Chief Financial Officer

Chief Technology Officer

Chief Administrative Officer

Chief of Business Development & Strategy

Chief Ethics & Compliance Officer

Leidos has an office in Reston

Reston, US (HQ)

11951 Freedom Dr

Leidos's revenue was reported to be $2.6 b in Q1, 2017

USD

## Revenue (Q1, 2017) | 2.6 b |

## Gross profit (Q1, 2017) | 310 m |

## Gross profit margin (Q1, 2017), % | 12% |

## Net income (Q1, 2017) | 74 m |

## EBIT (Q1, 2017) | 141 m |

## Market capitalization (17-Aug-2017) | 8.4 b |

## Cash (31-Mar-2017) | 206 m |

Leidos's current market capitalization is $8.4 b.

- Source: SEC Filings

USD | Y, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## Revenue | 5.8 b | 5.1 b | 7 b |

## Revenue growth, % | (12%) | 39% | |

## Cost of goods sold | 4.1 b | ||

## Gross profit | 2.9 b | ||

## Gross profit Margin, % | 41% | ||

## General and administrative expense | 201 m | ||

## Operating expense total | 201 m | ||

## EBIT | (214 m) | 320 m | |

## EBIT margin, % | (4%) | 5% | |

## Interest expense | (53 m) | ||

## Interest income | 4 m | ||

## Pre tax profit | 355 m | ||

## Income tax expense | (112 m) | ||

## Net Income | (323 m) | 246 m |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Revenue | 1.3 b | 1.3 b | 1.2 b | 1.3 b | 1.3 q | 1.3 b | 1.3 b | 1.9 b | 2.6 b |

## Cost of goods sold | 1.1 b | 1.1 b | 1.1 b | 1.1 b | 1.1 q | 1.2 b | 1.1 b | 1.6 b | 2.3 b |

## Gross profit | 187 m | 161 m | 153 m | 144 m | 160 t | 158 m | 147 m | 238 m | 310 m |

## Gross profit Margin, % | 14% | 13% | 12% | 11% | 12% | 12% | 11% | 13% | 12% |

## General and administrative expense | 87 m | 72 m | 75 m | 51 m | 53 t | 60 m | 57 m | 87 m | 144 m |

## Operating expense total | 87 m | 72 m | 75 m | 51 m | 53 t | 60 m | 57 m | 87 m | 144 m |

## EBIT | (410 m) | 72 m | 38 m | 64 m | 94 t | 89 m | 75 m | 101 m | 141 m |

## EBIT margin, % | (31%) | 6% | 3% | 5% | 7% | 7% | 6% | 5% | 5% |

## Interest expense | (20 m) | (18 m) | (14 m) | (14 m) | (14 t) | (11 m) | (13 m) | (28 m) | (38 m) |

## Interest income | 1 m | 3 m | 2 m | ||||||

## Pre tax profit | (430 m) | 54 m | 23 m | 52 m | 80 t | 78 m | 60 m | 75 m | 108 m |

## Income tax expense | (9 m) | (16 m) | (15 m) | (31 t) | (29 m) | (19 m) | 17 m | (34 m) | |

## Net Income | (438 m) | 34 m | 41 m | 37 m | 49 t | 49 m | 41 m | 92 m | 74 m |

- Source: SEC Filings

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## Cash | 430 m | 443 m | 376 m |

## Current Assets | 1.8 b | 1.6 b | 2.4 b |

## PP&E | 483 m | 308 m | 259 m |

## Goodwill | 1.7 b | 1.2 b | 4.6 b |

## Total Assets | 4.2 b | 3.3 b | 9.1 b |

## Accounts Payable | 1.4 b | ||

## Dividends Payable | 23 m | ||

## Current Liabilities | 1 b | 951 m | 2 b |

## Additional Paid-in Capital | 1.6 b | 1.4 b | 3.3 b |

## Retained Earnings | 25 m | (177 m) | |

## Total Equity | 1.6 b | 998 m | 3.1 b |

## Financial Leverage | 2.6 x | 3.3 x | 2.9 x |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Cash | 358 m | 418 m | 377 m | 365 m | 635 m | 609 m | 670 m | 449 m | 206 m |

## Current Assets | 1.7 b | 1.7 b | 1.7 b | 1.7 b | 1.7 b | 1.8 b | 1.8 b | 2.6 b | 2.4 b |

## PP&E | 231 m | 238 m | |||||||

## Goodwill | 1.2 b | 1.2 b | 1.2 b | 1.2 b | 1.2 b | 1.2 b | 1.2 b | 4.9 b | 4.6 b |

## Total Assets | 3.5 b | 3.4 b | 3.3 b | 3.2 b | 3.3 b | 3.4 b | 3.4 b | 9.6 b | 9.1 b |

## Accounts Payable | 682 m | 704 m | 745 m | 716 m | 771 m | 707 m | 720 m | 1.5 b | 592 m |

## Dividends Payable | 23 m | 21 m | |||||||

## Current Liabilities | 991 m | 1 b | 987 m | 996 m | 1 b | 1 b | 990 m | 2 b | 2 b |

## Additional Paid-in Capital | 1.4 b | 1.4 b | 1.4 b | 1.3 b | 1.3 b | 1.4 b | 1.4 b | 3.3 b | 3.3 b |

## Retained Earnings | (419 m) | (406 m) | (380 m) | (251 m) | (230 m) | (188 m) | (154 m) | ||

## Total Equity | 919 m | 954 m | 1.1 b | 1.1 b | 3.1 b | 3.2 b | |||

## Financial Leverage | 3.5 x | 3.5 x | 3.1 x | 3 x | 3.1 x | 2.9 x |

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## Net Income | 164 m | (323 m) | 242 m |

## Depreciation and Amortization | 81 m | 62 m | 41 m |

## Cash From Operating Activities | 13 m | ||

## Purchases of PP&E | (53 m) | (29 m) | (27 m) |

## Long-term Borrowings | (39 m) | ||

## Dividends Paid | (95 m) | (93 m) |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Net Income | (438 m) | 34 m | 41 m | 37 m | 49 t | 49 m | 41 m | 92 m | 74 m |

## Accounts Payable | 592 m |

USD | Y, 2017 |
---|---|

## Revenue/Employee | 78.2 k |

## Financial Leverage | 2.9 x |

Leidos's Locations was reported to be 341 in FY, 2016, which is a 44% increase from the previous period

- Source: SEC Filings

Source: 158 public H-1B filings from Leidos

June 23, 2016

* Awarded a subcontract by leidos to evaluate
immunovaccine's depovax(tm) platform for development of peptide
based malaria vaccine targets
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)